Curated news and analysis on clinical trials, drug approvals, and medical research.
BriaCell Therapeutics transfers exclusive license for Soluble CD80 cancer therapy to subsidiary BriaPro in deal valued at C$1.18 million, with BriaCell retaining 78% stake and providing $3 million credit facility.
Multiple Indian drugmakers begin selling generic versions of Ozempic and Wegovy following March patent expiration, with prices 50-60% below branded counterparts. The launches signal global pricing shifts as Novo Nordisk faces patent losses across multiple markets.
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter, with AMG National Trust Bank, Cibc World Market Inc., and Advisors Asset Management Inc. increasing holdings by approximately 20%.
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
Researchers demonstrate that a fully implanted brain device can detect walking states in Parkinson's patients during unsupervised daily activities, opening the door to adaptive deep brain stimulation therapies that adjust to real-world movement.
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.
A 30-year-old female with stage IV gallbladder adenocarcinoma achieved complete metabolic resolution of metastases after three cycles of pembrolizumab, gemcitabine, and cisplatin, despite presenting without traditional risk factors.
Kingman Minerals Ltd. has received approval from the Arizona Department of Water Resources to drill seven exploration holes for Phase III at its Mohave Project, with drilling set to begin February 25, 2026.
Sixty Republican members of Congress filed an amicus brief supporting Louisiana's lawsuit to restore in-person dispensing requirements for mifepristone, challenging Biden-era rules allowing mail-order abortion drugs.
Multiple institutional investors modified their positions in AstraZeneca during the third quarter, with new stakes and adjustments reported in SEC filings. The company announced a dividend of $1.595 per share payable March 23rd.
Life sciences companies are integrating AI into clinical trial operations to reduce administrative burden and improve efficiency, while the biotechnology sector experiences a structural transformation driven by AI industrialization and institutional capital.
Syndax Pharmaceuticals partnered with World Orphan Drug Alliance to launch a Managed Access Program for Revuforj in multiple regions. A price target was raised to $28 while maintaining a Buy rating.
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
Ultragenyx Pharmaceutical announced positive long-term clinical data for UX111 gene therapy for Sanfilippo syndrome Type A, with up to 8.5 years of follow-up showing sustained biomarker reductions and functional improvements. The company resubmitted its BLA to the FDA in January 2026.
Three new computational approaches enhance molecular property prediction and drug design through advanced neural networks, multimodal learning, and thermodynamic analysis of receptor-ligand interactions.
The Southwest Florida Water Management District declared a Modified Phase II Water Shortage Order on Feb. 8 following a 13-inch rainfall deficit, imposing mandatory once-a-week watering restrictions and a 5 percent water usage surcharge across the region.
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
Tempus AI partners with Median Technologies to integrate FDA-cleared eyonis LCS lung cancer screening software into its Pixel platform, marking the first US distribution agreement for the diagnostic tool.
A population-based study of over 1.27 million births found SSRI antidepressants during pregnancy increase gestational diabetes risk but reduce preterm birth and low birth weight risks, with effects independent of maternal depression.
Investigation reveals prescription-only weight-loss drugs Mounjaro and Wegovy are easily accessible in India without proper medical oversight, as semaglutide goes off-patent next month with prices expected to drop 70 percent.
